BRSK2 Inhibitors

CGP 57380 is a selective BRSK2 inhibitor that modulates neuronal signaling pathways by targeting the kinase domain with high specificity. Its unique molecular interactions involve a combination of electrostatic and van der Waals forces, which stabilize the inhibitor-enzyme complex. The compound exhibits distinct reaction kinetics, characterized by a rapid association and slower dissociation, allowing for prolonged engagement with BRSK2. This dynamic behavior influences downstream cellular processes, highlighting its role in fine-tuning kinase activity.

LY 294002 could downregulate BRSK2 by inhibiting phosphoinositide 3-kinases (PI3K), potentially leading to a reduction in the PI3K/AKT pathway-mediated BRSK2 synthesis.

Rapamycin may decrease BRSK2 expression by binding to FKBP12 and inhibiting mammalian target of rapamycin (mTOR), a kinase that promotes protein synthesis, including that of BRSK2.

SP600125 has the potential to inhibit BRSK2 synthesis by blocking c-Jun N-terminal kinase (JNK), which is involved in stress response pathways that can control neuronal gene expression.

SB 203580 might reduce BRSK2 transcript levels by selectively inhibiting p38 MAP kinase, thereby interfering with the kinase's role in cell cycle control and apoptotic gene expression, including BRSK2.

PD 98059 could inhibit BRSK2 by blocking mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinases that drive the expression of various neuronal genes.

Wortmannin might downregulate BRSK2 by irreversibly inhibiting PI3K, leading to a reduction in AKT kinase activity and subsequent decrement in neuronal survival signals that include BRSK2 expression.

Triciribine may inhibit BRSK2 expression by targeting AKT, resulting in decreased protein synthesis machinery activity, which is crucial for the maintenance of various neuronal proteins.

LY3214996 could suppress BRSK2 by inhibiting ERK1 and ERK2, leading to a decrease in MAPK pathway signaling and subsequent downregulation of associated gene expression.

PF 4708671 has the potential to decrease BRSK2 levels by specifically inhibiting p70 ribosomal S6 kinase (p70S6K), which plays a role in the translation of a subset of mRNAs encoding proteins like BRSK2.